PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35074264-0	2022	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.	olaparib	0-8	BRCA1 DNA repair associated	Homo sapiens	73-80	
35074264-0	2022	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.	olaparib	0-8	BRCA1 DNA repair associated	Homo sapiens	111-118	
35074264-3	2022	This study examines the use of olaparib in patients with metastatic breast cancer harboring sBRCA1/2 or germline or somatic non-BRCA1/2, HRR mutations and demonstrates potential activity of PARPi in this setting.	olaparib	31-39	BRCA1 DNA repair associated	Homo sapiens	128-135	
35074264-4	2022	METHODS: In this retrospective, single institution study, patients who were treated with off-label, off-protocol olaparib for metastatic breast cancer harboring sBRCA1/2 or germline or somatic non-BRCA1/2, HRR mutations were identified.	olaparib	113-121	BRCA1 DNA repair associated	Homo sapiens	197-204